Our First Step Towards Manufacturing in the US
May 28, 2020
MedPharm Ltd, a world-leading contract developer of topical and transdermal pharmaceutical products, has taken the first steps to expand its manufacturing capacity in the US to complement an existing manufacturing facility in the UK. MedPharm has obtained a facility in Durham, NC which will house liquid and semi-solid manufacturing and packaging capabilities with an initial capacity of up to 250kg. Located within a few miles of MedPharm’s current Center of Excellence in RTP, this facility is expected to complete initial qualification by the start of Q4 2020.
The new site gives MedPharm’s US based clients the opportunity to manufacture clinical batches and early stage development scale domestically. The facility is expected to further expand the number and type of manufacturing lines in the future based on market demand.
“MedPharm’s investment in this facility is a clear demonstration of our commitment to a global vision to expand services downstream towards manufacturing’ stated Eugene Ciolfi, MedPharm’s President and CEO. “MedPharm can now offer both clinical manufacture and formulation development for topical products in North America to complement similar services established for 20 years in the UK.”
MedPharm is the world’s leading contract provider of topical and transdermal formulation development and manufacturing services. Our experts specialize in reducing risk and accelerating development times for generic and proprietary pharmaceutical customers through cost-effective and industry-leading performance testing models. Well-established as the global leader in dermal and transdermal product development, MedPharm also offers innovative solutions for airway, ophthalmic, otic, ungual, and other topical preparations. With locations in both the US and the UK, MedPharm is the CDMO of choice for developers around the globe.